A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.

Jian Li(National Center on Birth Defects and Developmental Disabilities), Lin Shen(Hangzhou Normal University), Yi Huang(Hubei Cancer Hospital), Quanli Gao(Zhengzhou University), Huanli Wang(University of Science and Technology of China), Ying Yuan(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Ye Xu(Central South University of Forestry and Technology), Aimin Zang(Affiliated Hospital of Hebei University), Yunong Gao, Jing Wang(Central South University), Dong Wang(Chongqing University), Tianshu Liu(Sun Yat-sen University), Jianming Xu(Chinese PLA General Hospital), Yanqiao Zhang(Harbin Medical University), Haiping Jiang, Chunmei Shi(Fujian Medical University), Zhezhen Li(BeiGene (China)), Shou Liu(Qinghai University), Yanhong Deng(Sun Yat-sen University)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.2569
Cited by 15

Related Papers

Semiconductor heterojunction photocatalysts: design, construction, and photocatalytic performances
|Chemical Society Reviews|2014|4.1k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701